Curis
CRIS----
Curis (CRIS)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Curis Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$168.333504.57%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · 20 hours ago
CRIS Q2'26 Earnings: revenue estimate is 1.00M USD
- Quartr · 1 day ago, 09:05 AM
CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials
- Quartr · 1 day ago, 06:15 AM
CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding
- Unusual Whales · 1 day ago, 06:11 AM
Curis Announces Positive Emavusertib Update
- PUBT · 1 day ago, 06:04 AM
Curis notifies press release availability on positive emavusertib update
- StockTitan · Jul 6 at 12:30 AM
Curis Consents First Six Patients in TakeAim CLL Study | CRIS Stock News
